Daiichi Sankyo Japan in the news

Daiichi Sankyo's Enhertu and Datroway received approvals in Japan for new first-line metastatic breast cancer indications, marking significant advancements in treatment options.

Malaysia's IHH Healthcare unit lost a Tokyo court case against Daiichi Sankyo regarding damages over its 2018 acquisition of a stake in India's Fortis Healthcare.

IHH Healthcare's unit lost its court claim against Daiichi Sankyo in Japan and was ordered to pay litigation costs.

Daiichi Sankyo is strategically investing in new cancer drugs and divesting its over-the-counter unit to fuel oncology growth and reduce dependency on its blockbuster Enhertu before its patent expires.

Daiichi Sankyo presented a five-year business plan to become a top five global oncology company by 2035 by maximizing its ADC portfolio and launching over 20 new indications.

Daiichi Sankyo's Enhertu is now approved in Japan as a second-line treatment for HER2-positive gastric cancer, showing improved survival rates.

Nuvation Bio secured global rights for the cancer drug safusidenib from Daiichi Sankyo, including for Japan, enabling expanded clinical trials.

A Japanese expert panel has approved Daiichi Sankyo's MMR vaccine for production and sale, potentially making it the sole option in Japan.

Vanflyta, a targeted therapy for FLT3-ITD mutation–positive AML, gained Korean approval for use with chemotherapy and as maintenance, improving survival outcomes.

Daiichi Sankyo secured Chinese approval for ENHERTU in HER2-positive metastatic gastric cancer, reinforcing its oncology pipeline but facing short-term financial and execution challenges.

Daiichi Sankyo's ENHERTU gained China approval for gastric cancer, reinforcing its ADC oncology platform amid pipeline expansion and execution risks.

Daiichi Sankyo's Enhertu and Datroway ADCs are advancing in cancer treatment but face market and clinical complexities including competition, treatment strategies, and safety management.

Daiichi Sankyo's ENHERTU gained China approval for HER2 positive metastatic gastric cancer, reinforcing its oncology growth strategy amid ongoing regulatory and safety considerations.

Daiichi Sankyo opened a permanent Toronto headquarters to expand oncology research, clinical trials, and healthcare partnerships in Canada.

Dato-DXd by AstraZeneca and Daiichi Sankyo is a promising antibody-drug conjugate for advanced solid tumors, with expected market growth and regulatory progress through 2034.

Veronika Rozehnal succeeds Jürgen Müller as head of Daiichi Sankyo's European Translational Research Center, which has grown significantly under Müller's leadership.

Daiichi Sankyo plans a ¥39 dividend with a 2.5% yield, but dividend sustainability is uncertain due to lack of free cash flow despite strong earnings growth.

Enhertu gained Chinese approval for second-line HER2-positive gastric/GEJ cancer after showing survival benefits in a Phase III trial.

Daiichi Sankyo's latest results show revenue growth but profit decline due to increased R&D and one-time costs, with ongoing investments in innovative therapies and shareholder returns.

Veronika Rozehnal replaces Jürgen Müller as head of Daiichi Sankyo's Translational Research Center Europe, a key hub for preclinical drug research and innovation.